ZYBT Zhengye Biotechnology Co., Ltd.: Rasio Kapitalisasi Pasar marang Nilai Buku

Zhengye Biotechnology (ZYBT) relies on patent protection for its strains, providing the company with significant pricing power. However, fierce competition with local biolabs necessitates continuous investment in research and development. This chart on GURU.Markets reflects the asset's price action, where the indicator stands at 1.89. Business growth is driven by expansion into the B2B segment and the market launch of new treatments against swine flu.

The market-to-book ratio assesses the investor's premium over the company's net assets by comparing market capitalization with the actual value of assets minus liabilities. Analyzing the current price-to-book ratio of 1.89 provides insight into how the market values the potential of Zhengye Biotechnology (ZYBT) in joint developments of vaccines and diagnostic systems with agricultural enterprises and veterinary clinics.